Date posted: 2 June 2022
Amplia has released new data showing that in a head-to-head preclinical comparison, using a mouse model of idiopathic pulmonary fibrosis (IPF), AMP945 showed comparable efficacy to the current standard of care.
The current pharmaceutical standards of care for idiopathic pulmonary fibrosis (IPF) are either OFEV® (nintedanib) or Esbriet® (pirfenidone). Both have side effect profiles which limit their use, and efforts are underway to find more tolerable and effective treatments for this debilitating disease.
In the model, mice with lung fibrosis were treated with inactive Vehicle, AMP945, OFEV® or AMP945 + OFEV® for 14 days. Following treatment, the efficacy of AMP945 and OFEV® were measured using the Ashcroft score to quantify the extent of lung fibrosis in lung samples. The results showed that AMP945 and OFEV® reduce lung fibrosis to a similar and statistically significant extent compared to treatment with the inactive Vehicle.
Amplia CEO and Managing Director, Dr John Lambert, commented:
“This result reconfirms the efficacy of AMP945 in a well-recognised IPF model and shows that, in the model, AMP945’s activity is comparable to that of OFEV®. This information is highly encouraging, both as we design our clinical trials in people with IPF and in our ongoing discussions with potential commercial and strategic partners.”
- Click here to review today’s ASX release
- Interviews: Amplia CEO and Managing Director, Dr John Lambert, is available for comment.
